BCM
XGN icon

BlueCrest Capital Management’s Exagen XGN Stock Holding History

BlueCrest Capital Management’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$60.8K – 287
2025
Q4 		$60.8K Buy
+10,000
New +$91K ﹤0.01% 169

Other funds holding XGN

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return

BlueCrest Capital Management's XGN Position: Q1 2026 in Review

BlueCrest Capital Management sold out of Exagen (XGN) in Q1 2026, closing a stake of 10,000 shares — an estimated $60.8K sold.

BlueCrest Capital Management first reported a position in XGN in Q4 2025 and held it in 1 quarter. The position peaked at $60.8K in Q4 2025. 61 funds tracked by Wall St. Rank hold XGN as of Q1 2026.

  • BlueCrest Capital Management reported no remaining Exagen position as of Q1 2026 after selling out during the quarter.
  • BlueCrest Capital Management sold 10,000 Exagen shares in Q1 2026, an estimated $60.8K.
  • BlueCrest Capital Management first reported a position in Exagen in Q4 2025 and held it in 1 quarter.
  • BlueCrest Capital Management's Exagen position peaked at $60.8K in Q4 2025.
  • 61 funds tracked by Wall St. Rank held Exagen as of Q1 2026.

Based on BlueCrest Capital Management's 13F filing for Q1 2026, filed 15 May 2026.